Bruce Greenberg - 09 Mar 2024 Form 4 Insider Report for Aldeyra Therapeutics, Inc. (ALDX)

Role
Interim Chief Financial Officer
Signature
/s/ Bruce Greenberg
Issuer symbol
ALDX
Transactions as of
09 Mar 2024
Net transactions value
-$44,968
Form type
4
Filing time
12 Mar 2024, 20:07:22 UTC
Previous filing
02 Mar 2023
Next filing
17 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALDX Common Stock Sale $44,968 -13,201 -9.9% $3.41 120,699 11 Mar 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALDX Stock Option (right to buy) Award $0 +252,280 $0.000000 252,280 09 Mar 2024 Common Stock 252,280 $3.62 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards.
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.27 to $3.58. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2024.

Remarks:

Interim Chief Financial Officer